EWA
IMVT icon

EverSource Wealth Advisors’s Immunovant IMVT Stock Holding History

EverSource Wealth Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Sell
269
-210
-44% -$6.4K ﹤0.01% 2893
2026
Q1 		$11.9K Buy
479
+192
+67% +$4.97K ﹤0.01% 2824
2025
Q4 		$7.3K Buy
287
+242
+538% +$5.4K ﹤0.01% 2949
2025
Q3 		$726 Buy
45
+29
+181% +$469 ﹤0.01% 3843
2025
Q2 		$256 Sell
16
-187
-92% -$2.83K ﹤0.01% 4023
2025
Q1 		$3.47K Buy
203
+186
+1,094% +$3.89K ﹤0.01% 2669
2024
Q4 		$421 Buy
17
+3
+21% +$85 ﹤0.01% 3253
2024
Q3 		$399 Hold
14
– – ﹤0.01% 2908
2024
Q2 		$407 Buy
14
+11
+367% +$313 ﹤0.01% 2931
2024
Q1 		$82 Buy
+3
New +$109 ﹤0.01% 2831

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's IMVT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Immunovant (IMVT) stake by 44% in Q2 2026, selling an estimated $6.4K and leaving 269 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

EverSource Wealth Advisors first reported a position in IMVT in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.9K in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • EverSource Wealth Advisors held 269 shares of Immunovant worth $10.4K as of Q2 2026.
  • EverSource Wealth Advisors sold 210 Immunovant shares in Q2 2026, an estimated $6.4K.
  • Immunovant made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2893 holding.
  • EverSource Wealth Advisors first reported a position in Immunovant in Q1 2024 and has held it in 10 quarters since.
  • EverSource Wealth Advisors's Immunovant position peaked at $11.9K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.